Core Laboratories Inc. /DE/ (CLB) · Oct 28, 2026 · Earnings

Core Lab earnings miss on EPS as international demand recovers

Miss — GAAP EPS $0.12 vs ~$0.16 consensus

Core Lab earnings showed recovering international demand and a slight revenue beat, but Q3 EPS missed consensus and Q4 guidance is broadly flat.

Core Lab is an oilfield-services specialist built around reservoir characterization and production-enhancement technologies, with the growth thesis increasingly tied to international and offshore activity while U.S. land activity remains more cyclical. Current published estimates called for roughly $131.9 million of revenue and $0.16 of EPS, making the quarter a revenue near-miss-to-beat but an earnings miss.

The top line recovered, but not enough to change the broader earnings trend. Q3 revenue rose 6.0% sequentially to $132.1 million and was down 1.8% year over year, modestly above the published consensus near $131.9 million. Reservoir Description led the rebound, up 7.1% sequentially, while Production Enhancement rose 4.1%. The mix supports the company’s international-recovery narrative, but nine-month revenue was still down 2.5% and operating income was down 43.1% year over year. (Statements of Operations; Segment Information)

MetricQ3 2026Q2 2026Q3 2025Versus expectation
Revenue$132.1M (Statements of Operations)$124.6M$134.5MSlightly above ~$131.9M consensus
GAAP EPS$0.12 (Statements of Operations)$0.12$0.31Below ~$0.16 consensus
Ex-items EPS$0.16 (Non-GAAP reconciliation)$0.11$0.22Roughly in line with adjusted expectation
Operating income$12.1M (Statements of Operations)$9.2M$20.9MDown 42.3% year over year
Free cash flow$1.7M (Free Cash Flow computation)——Positive, but modest

The miss came below revenue, not from a collapse in demand. Ex-items operating income rose 35% sequentially, but remained 24% below the prior year, while GAAP EPS was held down by a 41% effective tax rate and ongoing pressure from geopolitical disruptions. Reservoir Description’s 78% sequential incremental margin was encouraging, but Production Enhancement operating income fell 17.2% sequentially as delayed Gulf of America diagnostic projects offset stronger product sales. (Non-GAAP reconciliation; Segment Information)

The international recovery is real but still fragile. Reservoir Description revenue improved across Europe-Africa, Asia-Pacific, Latin America and the Middle East, and the company cited expanded Middle East analytical work plus an Australian appraisal program. However, Middle East demand remained below pre-conflict levels, and the company said early-Q4 attacks had already delayed regional projects. That makes the recovery story more dependent on a gradual normalization of international activity than on an immediate step-up. (Reservoir Description) 〔0〕

Q4 guidance keeps the recovery measured rather than accelerating. Revenue is projected at $128.5 million to $134.5 million, implying a roughly flat sequential quarter around the midpoint, with EPS of $0.12 to $0.20. The range is consistent with the company’s prior Q3 revenue and EPS framework, so the new information is mainly the confirmation that geopolitical delays and normal U.S. year-end seasonality are still limiting near-term growth. (Industry and Core Lab Outlook and Guidance) 〔1〕

Cash generation and capital allocation remain secondary positives, not enough to offset the earnings miss. The company generated $1.7 million of Q3 free cash flow, repurchased 87,873 shares for approximately $1.1 million, reduced net debt to $93.4 million, and maintained its $0.01 quarterly dividend. Those actions show balance-sheet control, but cash generation was modest relative to the company’s stated focus on free cash flow. (Liquidity, Free Cash Flow, Share Repurchases, and Dividend)

Bottom line: Core Lab’s operating story improved sequentially, especially internationally, but the quarter still missed the market’s EPS bar and Q4 points to stabilization rather than a breakout. The business is recovering, but the recovery remains exposed to geopolitical delays, elevated taxes and uneven margins.

What to watch next

Q3 earnings call, October 29, 2026

Original filing on SEC EDGAR

More Core Laboratories Inc. /DE/ news

Core Lab earnings miss on EPS as international demand recovers | CLB Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.